Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus PT from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $93.33.

A number of research firms have weighed in on PBH. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock traded down $1.06 during mid-day trading on Friday, reaching $79.84. 386,979 shares of the company's stock traded hands, compared to its average volume of 302,956. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20. The firm has a market capitalization of $3.95 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 2.43 and a beta of 0.45. Prestige Consumer Healthcare has a 12 month low of $64.94 and a 12 month high of $90.04. The firm has a 50 day moving average price of $84.16 and a two-hundred day moving average price of $82.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The business had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. During the same quarter in the prior year, the business posted $1.02 earnings per share. The business's quarterly revenue was up 7.0% on a year-over-year basis. On average, research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently bought and sold shares of PBH. Voya Investment Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 19.5% during the 1st quarter. Voya Investment Management LLC now owns 41,717 shares of the company's stock valued at $3,586,000 after purchasing an additional 6,798 shares during the last quarter. Strs Ohio purchased a new stake in shares of Prestige Consumer Healthcare in the first quarter worth about $318,000. Geneos Wealth Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares in the last quarter. Intech Investment Management LLC boosted its stake in Prestige Consumer Healthcare by 18.9% during the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company's stock valued at $2,348,000 after buying an additional 4,343 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock valued at $9,010,000 after buying an additional 70,330 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.